Timolol MaleateThird Party Manufacturing in India

Timolol Maleate is a non-selective beta-adrenergic receptor blocking agent that reduces intraocular pressure by decreasing the production of aqueous humour in the eye. It works by competitively blocking both beta-1 and beta-2 adrenergic receptors in the ciliary epithelium, the tissue responsible for producing the fluid that fills the front of the eye. When these receptors are blocked, cyclic AMP levels within the ciliary body decrease, which slows the active secretion of aqueous humour. This reduction in fluid production lowers the pressure inside the eye, preventing damage to the optic nerve. Timolol does not have significant intrinsic sympathomimetic activity, direct myocardial depressant activity, or local anaesthetic membrane-stabilising activity, making it a clean beta-blocker for ophthalmic use. The drug is the levo-isomer of timolol, which is more potent than the racemic mixture. Despite being applied topically as eye drops, a portion is absorbed systemically through the nasolacrimal duct, which can produce systemic beta-blocking effects.

Therapeutic Uses

Timolol Maleate Ophthalmic Solution is prescribed for the management of elevated intraocular pressure:

• Open-Angle Glaucoma: As a first-line or adjunctive therapy to lower IOP and prevent optic nerve damage
• Ocular Hypertension: For patients with elevated IOP who are at risk of developing glaucoma
• Adjunctive Therapy: Used in combination with prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-2 agonists for patients requiring additional pressure reduction
• Post-Surgical IOP Control: Used to manage pressure spikes following cataract or glaucoma surgery

Why Manufacturers Choose Timolol Maleate

Timolol Maleate is one of the most widely prescribed ophthalmic medications globally and is included on the WHO Essential Medicines List. The molecule has been off-patent for decades, creating an established generic market with consistent demand across India and export markets. Manufacturing in 0.25% and 0.5% solutions is a core competency for Indian ophthalmic producers, with the 0.5% 10ml bottle being the most prescribed strength. Its inclusion in multiple fixed-dose combinations with other glaucoma drugs further expands its commercial relevance.